KemPharm Inc. (NASDAQ:KMPH) fell 3.1% on Thursday . The company traded as low as $5.00 and last traded at $5.03, with a volume of 107,391 shares. The stock had previously closed at $5.19.

A number of equities research analysts have weighed in on KMPH shares. Royal Bank Of Canada restated a “buy” rating on shares of KemPharm in a report on Sunday, May 8th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Canaccord Genuity restated a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Finally, Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.

The company’s 50 day moving average is $4.18 and its 200-day moving average is $10.21. The stock’s market capitalization is $75.13 million.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.36. Analysts expect that KemPharm Inc. will post ($2.44) EPS for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.